Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin ® ) in patients with HER2-positive metastatic breast cancer

ConclusionsPF-05280014 and trastuzumab-EU had similar PK parameters and influential PK covariates in patients with HER2-positive mBC. These results provided further evidence in patients for PK similarity between PF-05280014 and trastuzumab-EU.Clinical trial registrationClinicalTrials.gov, NCT01989676.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research